Company Position Country
AMAL Therapeutics Founder and CEO Switzerland
Are immunotherapies still an investment eldorado?

Madiha Derouazi has been working on vector engineering and therapeutic cancer vaccines for over 12 years. She has a strong background in applied molecular and cellular biotechnology, with research interests at the interface of fundamental and translational research. Madiha Derouazi holds a PhD in Biotechnology from the Ecole Polytechnique Fédérale de Lausanne (EPFL), Switzerland and a Master in Biotechnology Engineering from the University of Technology of Berlin, Germany.

Continue your tour